

Test Report: Standard Test Method for Efficacy of Antimicrobial Agents against Viruses in Suspension using Feline Immunodeficiency Virus

Test Laboratory

BluTest Laboratories Ltd

Robertson Incubator (Level 4)

Robertson Building 56 Dumbarton Road Glasgow, G11 6NU

Identification of sample

Name of the product SAFE 4

Manufacturer Safe Solutions Ltd, Wharton Green House, Bostock, Winsford,

Cheshire, CW7 3BD 10 February 2006

Storage conditions Room temperature and darkness

Active substances Not Known

Test Method and its validation

Date of Delivery

Method SAFE4 was diluted and 0.8 ml mixed with 0.2 ml virus

suspension (DMEM + 5% FBS) and 0.1 ml sterile distilled water

Dilution-neutralization Virus CPE detected by antibody staining
Neutralizer Eagles minimal essential medium + 5% v/v foetal

bovine serum at 4°C.

Experimental Conditions

Period of analysis 21 – 28 July 2006 Product diluent used Sterile hard water

Product test concentrations 1.0 % V/V; 2.0 % V/V; 5.0% V/V

Contact times 5 minutes \pm 10s; Test temperature 20°C \pm 1°C Interfering substance 0.6 g/l foetal bovine serum

Stability of mixture Precipitate absent throughout the test

stability of mixture Precipitate absent throughout the test

Temperature of incubation $37^{\circ}\text{C} \pm 1^{\circ}\text{C} + 5\% \text{ CO}_2$ Identification of virus Feline Immunodeficiency Virus/CRFK Cells

Conclusion

SAFE 4 retains virucidal activity at 5 minutes contact, at 2 % V/V and 5% V/V, (reduction in viral viability, 3.10 and 3.2 0 Log_{10} respectively) contact at 20°C under clean conditions (0,6 g/L protein as foetal bovine serum) for suspensions of Feline Immunodeficiency Virus.

Signed

Dr Chris Woodall Director, BluTest Laboratories Ltd Glasgow, UK 24 June 2010



SAFE 4 DISINFECTANT TESTED AGAINST FELINE IMMUNODEFICIENCY VIRUS

VANTOCIL IB CONCENTRATION	Contact time.	Log ₁₀ reduction in virus viability (mean of 4 samples, 6 replicates/sample)
1.0 % V/V	5 minutes	1.0 = FAIL
2.0 % V/V	5 minutes	3.1 = PASS
5.0 % V/V	5 minutes	3.2 = PASS

Controls	
CELL CULTURE	Cell death was not observed (2 replicates/sample controlled for each sample).
CYTOTOXICITY	Cytotoxicity was not observed at a greater dilution than 10 ⁻² . This restricts the
	sensitivity of the assay to <2.5 Log ₁₀ . TCID ₅₀ units/ml (2 samples, 6 replicates/sample).
VIRUS	Virus infectivity was observed at dilutions at 10 ⁻² . (2 samples, 6 replicates/sample).

DISCLAIMER

BluTest (BT) has performed the Testing detailed in this report using reasonable skill and care and that BT has used reasonable endeavors to carry out the Testing. All forecasts, recommendations and results contained in any report to the Company shall be submitted in good faith. However, other than as expressly set out in this report, no warranty is given (i) in relation to the Testing or the use(s) to which any results or deliverables produced in the course of the Testing are or may be put by the Company or their fitness or suitability for any particular purpose or under any special conditions notwithstanding that any such purpose or conditions may have been made known to BT or (ii) that the intended results or deliverables from the Testing can be achieved or (iii) that the Company can freely make use of the results or the deliverables without infringing any third party intellectual property rights and the Company will be deemed to have satisfied itself in this regard. BT shall have no liability (which is hereby excluded to the fullest extent permissible by law) in respect of any loss, liability or damage, including without limitation any indirect and/or consequential loss such as loss of profit or loss of business, market or goodwill, that the Company may suffer directly or indirectly as a result of or in connection with: (i) the performance of the Testing, except for direct loss arising from a breach of the foregoing warranties; (ii) the use of any materials, samples or other information provided by the Company for use in the Testing; and (iii) the Company's reliance upon or use of any results or deliverables provided as part of the Testing. The total liability of BT shall not exceed the sums paid to BT for the performance of the Testing.